WallStreetZenWallStreetZen

NASDAQ: BLRX
Biolinerx Ltd Stock Forecast, Predictions & Price Target

Analyst price target for BLRX

Based on 1 analyst offering 12 month price targets for Biolinerx Ltd.
Min Forecast
$21.00+3,552.17%
Avg Forecast
$21.00+3,552.17%
Max Forecast
$21.00+3,552.17%

Should I buy or sell BLRX stock?

Based on 1 analyst offering ratings for Biolinerx Ltd.
Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their BLRX stock forecasts and price targets.

BLRX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-04-17

1 of 1

Forecast return on equity

Is BLRX forecast to generate an efficient return?
Company
N/A
Industry
N/A
Market
35.16%

Forecast return on assets

Is BLRX forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

BLRX revenue forecast

What is BLRX's revenue in the next 2 years based on estimates from 2 analysts?
Avg 1 year Forecast
$14.4M+199.27%
Avg 2 year Forecast
$27.8M+478.54%
BLRX's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

BLRX revenue growth forecast

How is BLRX forecast to perform vs Biotechnology companies and vs the US market?
Company
99.97%
Industry
37.04%
Market
9.92%
BLRX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
BLRX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

BLRX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
BLRX$0.58$21.00+3,552.17%Buy
IMRX$1.43$13.40+837.06%Buy
APLM$0.47$5.75+1,120.81%Strong Buy
AADI$1.68$20.50+1,120.24%Strong Buy
OCEA$1.26N/AN/A

Biolinerx Stock Forecast FAQ

Is Biolinerx Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: BLRX) stock is to Buy BLRX stock.

Out of 1 analyst, 0 (0%) are recommending BLRX as a Strong Buy, 1 (100%) are recommending BLRX as a Buy, 0 (0%) are recommending BLRX as a Hold, 0 (0%) are recommending BLRX as a Sell, and 0 (0%) are recommending BLRX as a Strong Sell.

If you're new to stock investing, here's how to buy Biolinerx stock.

What is BLRX's revenue growth forecast for 2024-2025?

(NASDAQ: BLRX) Biolinerx's forecast annual revenue growth rate of 99.97% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.04%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.92%.

Biolinerx's revenue in 2024 is $4,800,000.On average, 2 Wall Street analysts forecast BLRX's revenue for 2024 to be $15,608,853,355, with the lowest BLRX revenue forecast at $13,484,571,538, and the highest BLRX revenue forecast at $17,733,135,173.

In 2025, BLRX is forecast to generate $30,174,581,112 in revenue, with the lowest revenue forecast at $23,035,690,298 and the highest revenue forecast at $37,313,471,926.

What is BLRX's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: BLRX) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is BLRX's Price Target?

According to 1 Wall Street analyst that have issued a 1 year BLRX price target, the average BLRX price target is $21.00, with the highest BLRX stock price forecast at $21.00 and the lowest BLRX stock price forecast at $21.00.

The Wall Street analyst predicted that Biolinerx's share price could reach $21.00 by Apr 17, 2025. The average Biolinerx stock price prediction forecasts a potential upside of 3,552.17% from the current BLRX share price of $0.58.

What is BLRX's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: BLRX) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.